Inhibitors of NEDD8-activating enzyme
View Patent ↗Disclosed are chemical entities which are inhibitors of Nedd8-activating enzyme (NAE), namely, the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate and pharmaceutically acceptable salts thereof; solid state forms thereof; and prodrugs thereof. Also disclosed are methods of using the chemical entities to treat disorders such as cancer.
1. A chemical entity comprising the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate.
2. The chemical entity of claim 1 , wherein said chemical entity is the hydrochloride salt or a pharmaceutically acceptable solvate thereof.
3. The chemical entity of claim 2 , wherein said chemical entity is substantially crystalline Form I.
4. The chemical entity of claim 2 , wherein at least 70% by weight is crystalline Form I.
5. The chemical entity of claim 2 , wherein at least 80% by weight is crystalline Form I.
6. The chemical entity of claim 2 , wherein at least 90% by weight is crystalline Form I.
7. The chemical entity of claim 2 , wherein at least 95% by weight is crystalline Form I.
8. The chemical entity of any of claims 3 - 7 , wherein Form I is characterized by an x-ray powder diffraction (XRPD) pattern having peaks at 2θ angles of 4.5°, 15.2°, 21.3°, 21.8° and 24.0°.
9. The chemical entity of claim 8 , wherein Form I is characterized by an XRPD pattern having peaks at 2θ angles of 4.5°, 7.5°, 14.4°, 14.6°, 15.2°, 15.9°, 19.5°, 21.3°, 21.8°, 22.4°, 22.7°, 24.0° and 24.8°.
10. The chemical entity of claim 8 , wherein Form I is characterized by an XRPD pattern having peaks at 2θ angles of 4.5°, 7.5°, 8.9°, 9.8°, 13.3°, 14.4°, 14.6°, 15.2°, 15.9°, 17.2°, 19.5°, 20.0°, 21.3°, 21.8°, 22.4°, 22.7°, 24.0°, 24.8°, 25.7° and 26.4°.
11. The chemical entity of any of claims 3 - 7 , wherein Form I is characterized by an x-ray powder diffraction (XRPD) pattern having a reference peak with a 2θ angle of 4.5±0.3°, and having peaks at 2θ angles of 10.7°, 16.8°, 17.3° and 19.5° relative to the reference peak.
12. The chemical entity of any of claims 3 - 7 , wherein Form I is characterized by an x-ray powder diffraction (XRPD) pattern having a reference peak with a 2θ angle of 4.5±0.3°, and having peaks at 2θ angles of 3.0°, 9.9°, 10.1°, 10.7°, 11.4°, 15.0°, 16.8°, 17.3°, 17.9°, 18.2°, 19.5° and 20.3° relative to the reference peak.
13. The chemical entity of any of claims 3 - 7 , wherein Form I is characterized by an x-ray powder diffraction (XRPD) pattern having a reference peak with a 2θ angle of 4.5±0.3°, and having peaks at 2θ angles of 3.0°, 4.4°, 5.3°, 8.8°, 9.9°, 10.1°, 10.7°, 11.4°, 12.7°, 15.0°, 15.5°, 16.8°, 17.3°, 17.9°, 18.2°, 19.5°, 20.3°, 21.2° and 21.9° relative to the reference peak.
14. The chemical entity of any of claims 3 - 7 , wherein Form I is characterized by an XRPD pattern substantially as shown in FIG. 4 .
15. The chemical entity of any of claims 3 - 7 , wherein Form I is characterized by differential scanning calorimetry (DSC) thermogram characterized by an endotherm with a peak at about 135.7° C. with an onset at about 129.6° C.
16. The chemical entity of any of claims 3 - 7 , wherein Form I is characterized by a DSC thermogram substantially as shown in FIG. 5 .
17. The chemical entity of any of claims 3 - 7 , wherein Form I is characterized by a thermogravimetric analysis (TGA) thermogram characterized by weight loss of about 3.7% from about 100° C. to about 150° C.
18. The chemical entity of any of claims 3 - 7 , wherein Form I is characterized by a TGA thermogram substantially as shown in FIG. 6 .
19. A composition comprising, the chemical entity of claim 1 ,and a pharmaceutically acceptable carrier.
20. The composition of claim 19 suitable for oral administration.